Vibhudutta Awasthi

University of Oklahoma Health Sciences Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Metabolic (dysfunction)‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is a growing global health concern with no approved pharmacological treatments. At the same time, there are no standard methods to definitively screen for the presence of MASLD because of its progressive nature and symptomatic commonality with other disorders. Recent advances in molecular understanding of MASLD pathophysiology have intensified research on development of new drug molecules, repurposing of existing drugs approved for other indications, and an educated use of dietary supplements for its treatment and prophylaxis. This review focused on depicting the latest advancements in MASLD research related to small molecule development for prophylaxis or treatment and diagnosis, with emphasis on mechanistic basis at the molecular level.

Year:

2024

Collaborators (6)

Venkateswararao Eeda

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Priya Balasubramanian

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Madhan Subramanian

Associate Professor

Oklahoma State University

UNITED STATES
View details

Priyabrata Mukherjee

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Atul Pranay

Associate Staff Scientist

Oklahoma Medical Research Foundation

UNITED STATES
View details

Kenneth Humphries

Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details